about
Guidelines for the use and interpretation of assays for monitoring autophagyActivation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumorsEssential versus accessory aspects of cell death: recommendations of the NCCD 2015.Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death.Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemiaEffect of acute exercise on prostate cancer cell growthTargeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.Alternative signaling pathways regulating type I interferon-induced apoptosis.Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic.Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.Molecular characteristics of immunogenic cancer cell death.Immunogenicity of anthracyclines: moving towards more personalized medicine.Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death.Immunogenic cancer cell death: a key-lock paradigm.Autophagy: cancer therapy's friend or foe?Tumor cell-derived exosomes: a message in a bottle.Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells.Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death.Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin.Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members.Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin.Two distinct steps of Bak regulation during apoptotic stress signaling: different roles of MEKK1 and JNK1.Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis.Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway.Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin.Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes.Multitargeted therapies for multiple myeloma.Consensus guidelines for the detection of immunogenic cell death.Back to Stockholm for 'metabolism, epigenetics and cell death'.Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid.Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy.Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax.Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation.Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir.Effects of the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid, on apoptosis in human hepatoma HepG2 cells.Horizontal transfer of tumor DNA to endothelial cells in vivo.Second Cell Death Network symposium: the vital cell death
P50
Q21996341-5938C987-E78D-4728-A356-930D1E9A4C02Q29615665-6298A042-EA34-48F9-8F2B-723CA1D705D5Q30408769-DE51BCD3-BE3B-41DC-B496-4F828E7A28A5Q34130711-2EFD8F3F-939C-44A7-BCEF-305772B1F2F8Q34545292-A97DBB80-F903-423A-A7B9-399C801FB86AQ34825681-C1ED3D0F-F05C-458B-9B91-C88DEA5591D2Q35723957-4D1A8EC5-A971-41CB-B19F-3F29F425BB5EQ36351980-A35B2F28-FC9C-4467-B350-ADEDAFA1B276Q36931431-4B366A0E-D3EB-4D15-AF19-2B65D1504947Q36949870-23DA29E3-959B-4F66-ABBC-D584BF78AEF8Q37002804-6548C03D-020D-4AB7-B028-D7119125F797Q37114351-A96D9239-67AB-49FC-B6A0-690622433259Q37133168-B9E60C8B-5491-4A85-B9A7-1E1FB4A13A5EQ37198125-51B54CE2-A4F4-423D-B393-D59C8A222F3EQ37855922-96F25E41-1A6A-4904-8C47-35C0397EE033Q38002669-9876272D-7220-4CA7-B805-62864F738863Q39289749-FECD5EB8-6FDB-42B1-8D28-2DF12F28D263Q39698158-D77821DF-C1F9-459D-97A5-C3D97282BD6BQ39984426-22644CFC-D222-419D-97D4-0B6D0CA69E70Q40045975-9486C2DE-F3AD-4587-9185-0DD41FD5E8F1Q40048828-D671808E-F9E2-4E81-B0BE-A87D5DE82EBAQ40066545-B160A50F-B2F2-4906-9B31-4A308473B666Q40306488-B04C36B5-21BB-443B-A834-9B80390CFC28Q40417128-27874144-3F35-469F-AE0A-D496492BD2D3Q40571407-3711AF1F-111B-4135-8F66-2F34E5AB6879Q40709009-C3935273-4A54-4956-AE98-96EE27E47A96Q41226450-5C862F4E-AA29-42DE-9478-A18A33F7B3F3Q42063996-5DC9F2F0-DF26-462F-913B-90336A790A98Q42553556-2EE1EE64-4CC6-4AB7-8AC2-81E59AC87B26Q42553826-233D15FE-D06E-4A3A-BFBC-EFE1F6458DE7Q43605633-FD8A0A74-D827-4C7D-9526-EC8B36661D1AQ43991443-407FC04F-FAD4-4251-98D0-1EEA82FD175CQ44526170-329FC6AA-FD3D-45B9-BD1A-67FC90CD0E38Q45280801-2C44FE8A-EC4D-4501-BCA2-889DF810F001Q46071125-D9CB2A24-222E-48EB-8F6B-5D5894C907BAQ46507429-FBFF6891-A2B1-4CE3-B6F5-5F4AD9EABD91Q46615265-8D1CCDCB-412D-4B15-B31B-74ED4DE399E5Q50515219-70F4F303-EC55-4010-95C5-5EBA64FCC5FFQ51819789-7EF0B0BA-34B0-4EB3-94ED-1F7073A9D962Q57650384-C3E896D7-6EAC-4ECE-9635-0CAA192B55D6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Theocharis Panaretakis
@ast
Theocharis Panaretakis
@en
Theocharis Panaretakis
@es
Theocharis Panaretakis
@sl
type
label
Theocharis Panaretakis
@ast
Theocharis Panaretakis
@en
Theocharis Panaretakis
@es
Theocharis Panaretakis
@sl
prefLabel
Theocharis Panaretakis
@ast
Theocharis Panaretakis
@en
Theocharis Panaretakis
@es
Theocharis Panaretakis
@sl
P214
P5587
P906
P106
P21
P214
P31
P496
0000-0001-5754-6950
P5587
gdsvxcx05s48ptk
P569
1973-01-01T00:00:00Z
P7859
viaf-39352528